NCCN Guidelines® Insights: Thyroid carcinoma, version 2.2018: Featured updates to the NCCN Guidelines Journal Article


Authors: Haddad, R. I.; Nasr, C.; Bischoff, L.; Busaidy, N. L.; Byrd, D.; Callender, G.; Dickson, P.; Duh, Q. Y.; Ehya, H.; Goldner, W.; Haymart, M.; Hoh, C.; Hunt, J. P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D. M.; McIver, B.; Raeburn, C. D.; Ridge, J. A.; Ringel, M. D.; Scheri, R. P.; Shah, J. P.; Sippel, R.; Smallridge, R. C.; Sturgeon, C.; Wang, T. N.; Wirth, L. J.; Wong, R. J.; Johnson-Chilla, A.; Hoffmann, K. G.; Gurski, L. A.
Article Title: NCCN Guidelines® Insights: Thyroid carcinoma, version 2.2018: Featured updates to the NCCN Guidelines
Abstract: The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma. © National Comprehensive Cancer Network, Inc. 2018, All rights reserved.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 12
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-12-01
Start Page: 1429
End Page: 1440
Language: English
DOI: 10.6004/jnccn.2018.0089
PROVIDER: scopus c2 - 30545990
PUBMED: 30545990
DOI/URL:
Notes: JNCCN J. Nat. Compr. Cancer Netw. -- Export Date: 2 January 2019 -- Article -- Source: Scopus C2 - 30545990
Altmetric Score
MSK Authors
  1. Richard J Wong
    224 Wong
  2. Jatin P Shah
    536 Shah